CV Sciences (CVSI) Gains from Sales and Divestitures (2017 - 2019)

CV Sciences' (CVSI) quarterly Gains from Sales and Divestitures came in at $2.9 million in Q4 2019, up 47.5% quarter-over-quarter from $2.0 million in Q3 2017.

CV Sciences (CVSI) Gains from Sales and Divestitures (2017 - 2019) Analysis & Trends

CV Sciences has disclosed Gains from Sales and Divestitures across 2 years of filings, most recently posting $2.9 million for Q4 2019.

  • Gains from Sales and Divestitures for Q4 2019 came in at $2.9 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $2.9 million (changed N/A YoY), and the FY2019 annual result was $2.9 million, changed N/A from the prior year.
  • Gains from Sales and Divestitures came in at $2.9 million for Q4 2019 at CV Sciences, up from $2.0 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $2.9 million in Q4 2019 to a low of $1.0 million in Q1 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 38.77 Bn 35.04 Bn 1.97 Bn
2 Zoetis 34.11 Bn 32.16 Bn 1.62 Bn
3 United Therapeutics 23.68 Bn 21.53 Bn 648.10 Mn
4 Aurora Cannabis 16.48 Bn 16.40 Bn 33.43 Mn
5 Neurocrine Biosciences 16.19 Bn 14.88 Bn 800.70 Mn
6 Elanco Animal Health 11.44 Bn 11.01 Bn 785.00 Mn
7 Alkermes 7.28 Bn 6.77 Bn -116.06 Mn
8 Lantheus Holdings 6.48 Bn 5.98 Bn 230.92 Mn
9 Hims & Hers Health 6.35 Bn 5.60 Bn 396.79 Mn
10 CV Sciences - - 1.56 Mn

Historic Data

Download Data
DateValue
Dec 31, 2019 2.95 Mn
Dec 31, 2019 2.95 Mn
Sep 30, 2017 2.00 Mn
Sep 30, 2017 2.00 Mn
Jun 30, 2017 1.00 Mn
Jun 30, 2017 1.00 Mn
Mar 31, 2017 1.00 Mn
Mar 31, 2017 1.00 Mn